2. Search Result
Search Result
Results for "

antifibrotic+agent

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Peptides

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0673
    Pirfenidone
    75+ Cited Publications

    AMR69

    		 TGF-beta/Smad CCR Inflammation/Immunology Cancer
    Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
    Pirfenidone
  • HY-B0673R
    Pirfenidone (Standard)

    AMR69 (Standard)

    		 Reference Standards TGF-beta/Smad CCR Inflammation/Immunology Cancer
    Pirfenidone (Standard) is the analytical standard of Pirfenidone. This product is intended for research and analytical applications. Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
    Pirfenidone (Standard)
  • HY-B0673S1
    Deupirfenidone

    LYT-100; AMR69-d3

    		 Isotope-Labeled Compounds Others
    Deupirfenidone-d3 is the deuterium labeled Pirfenidone (HY-B0673). Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
    Deupirfenidone
  • HY-B0673S
    Pirfenidone-d5

    AMR69-d5

    		 TGF-beta/Smad CCR Inflammation/Immunology Cancer
    Pirfenidone-d5 (AMR69-d5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities .
    Pirfenidone-d5
  • HY-147243
    Ansornitinib

    ANG-3070

    		 VEGFR PDGFR Cardiovascular Disease Inflammation/Immunology
    Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .
    Ansornitinib
  • HY-177739
    Antifibrotic agent 2

    		Drug Derivative Collagen Inflammation/Immunology
    Antifibrotic agent 2 (Compound 636) is a polycyclic pyridinone derivative with antifibrotic activity. Antifibrotic agent 2 reduces the pathological accumulation of fibrosis-related proteins such as fibronectin and collagen, prevents excessive fibrous connective tissue from depositing in organs or tissues, and reverses or delays the remodeling of tissue fibrosisby regulating the abnormal proliferation and activation of fibroblasts. Antifibrotic agent 2 can be used for research on pulmonary fibrosis .
    Antifibrotic agent 2
  • HY-176194
    Antifibrotic agent 1

    		Collagen c-Fms PDGFR Src Inflammation/Immunology
    Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model .
    Antifibrotic agent 1
  • HY-117485
    CBR-096-4

    		Hedgehog Inflammation/Immunology
    CBR-096-4 is a derivative of Itraconazole (HY-17514). CBR-096-4 is an orally active antifibrotic agent with no CYP3A4 inhibitory activity. CBR-096-4 inhibits the formation of matrix-secreting activated myofibroblasts (MFBs) from multiple tissue types. CBR-096-4 inhibits Hedgehog reporter activity (GLI-LUC), VEGF-dependent growth, and αSMA-LUC reporter activity. CBR-096-4 can be used for research of fibrosis .
    CBR-096-4
  • HY-P11827
    C11 peptide-1

    		Collagen ERK TGF-beta/Smad Metabolic Disease
    C11 peptide-1 is an antifibrotic agent that binds directly to Collagen I. C11 peptide-1 physically disrupts Collagen I interaction with Lumican. C11 peptide-1 reduces inflammatory infiltration and inhibits the ERK1/2 and Smad2/3 signaling pathways. C11 peptide-1 can be used for the research of liver fibrosis .
    C11 peptide-1
  • HY-181741
    PI3K-001

    		Cathepsin Inflammation/Immunology
    PI3K-001 is a cathepsin B-responsive prodrug and antifibrotic agent. PI3K-001 undergoes cathepsin B-mediated cleavage of the Val-Ala linker in fibrotic lung lesions to release an active PI3K inhibitor payload, while it remains stable in healthy tissues. PI3K-001 improves collagen deposition, tissue collapse and alveolar injury in fibrotic lung tissues. PI3K-001 is applicable for the research of pulmonary fibrosis .
    PI3K-001
  • HY-182038
    TGF-β1/Smad3-IN-2

    		VD/VDR TGF-beta/Smad Collagen Hippo (MST) Metabolic Disease
    TGF-β1/Smad3-IN-2 is an orally active antifibrotic agent. TGF-β1/Smad3-IN-2 has high affinity for VDR and can inhibit the TGFβ/SMAD3 signaling pathway. TGF-β1/Smad3-IN-2 inhibits hepatic stellate cell activation, reduces extracellular matrix deposition, and alleviates liver fibrosis in a bile duct ligation mouse model. TGF-β1/Smad3-IN-2 can be used for the research of liver fibrosis .
    TGF-β1/Smad3-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: